SCHEMBL17135279

SCHEMBL17135279

COC(=O)c1cnc(S(N)(=O)=O)c(Cl)c1Nc1cc(Cl)ccc1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.41
▸ PTGS2 P35354 2/20 0.41
▸ RAPGEF4 Q8WZA2 1/20 0.41
▸ ABL1 P00519 1/20 0.40
▸ ALDH1A1 P00352 2/20 0.39
▸ LMNA P02545 2/20 0.39
▸ CSF1R P07333 2/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ USP2 O75604 1/20 0.39
▸ PABPC1 P11940 1/20 0.39
▸ CA12 O43570 1/20 0.39
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ CA9 Q16790 1/20 0.39
▸ AURKA O14965 1/20 0.38
▸ AURKB Q96GD4 1/20 0.38
▸ POLB P06746 2/20 0.38
▸ NUDT1 P36639 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17135316 0.91 MAPT (0.41) MAPTPTGS2RAPGEF4ABL1ALDH1A1
SCHEMBL17134813 0.89 CLCN2 (0.43) MAPTPTGS2RAPGEF4ALDH1A1LMNA
SCHEMBL17135191 0.85 RAPGEF4 (0.46) MAPTPTGS2RAPGEF4ABL1ALDH1A1
SCHEMBL17134615 0.83 RAPGEF4 (0.44) MAPTPTGS2RAPGEF4ABL1ALDH1A1
SCHEMBL17134834 0.81 CSF1R (0.51) MAPTLMNACSF1RMEN1KMT2A
SCHEMBL17156862 0.78 LMNA (0.45) MAPTRAPGEF4ABL1ALDH1A1LMNA
SCHEMBL17134539 0.76 CSF1R (0.47) CSF1RCA1CA2CA9
SCHEMBL17135098 0.76 DRD2 (0.38) MAPTALDH1A1CA12CA1CA2
SCHEMBL17134702 0.76 KMT2A (0.47) MAPTLMNAMEN1KMT2ACA12
SCHEMBL17134796 0.76 FASN (0.38) MAPTLMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2927214-B1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND KYOWA HAKKO KIRIN CO LTD (JP) 2018-03-21 — — EP disclosed
US-9701689-B2 Substituted pyridines and pyridazines as CCR10 receptor inhibitors KYOWA HAKKO KIRIN CO., LTD. (JP) 2017-07-11 — — US disclosed
US-20150299214-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND KYOWA HAKKO KIRIN CO., LTD. (JP) 2015-10-22 — — US disclosed
EP-2927214-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND Kyowa Hakko Kirin Co., Ltd. (JP) 2015-10-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150299214-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND ARG1, H1-0, TYR MAPT 4384/4885PTGS2 3410/4885RAPGEF4 4515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback